<DOC>
	<DOCNO>NCT00175825</DOCNO>
	<brief_summary>This trial evaluate efficacy safety brivaracetam ( dose 5 , 20 50 mg/day twice day administration ) add-on therapy subject focal epilepsy .</brief_summary>
	<brief_title>A Dose-ranging Study With Brivaracetam Patients From 16 65 Years With Refractory Partial Onset Seizures .</brief_title>
	<detailed_description />
	<mesh_term>Seizures</mesh_term>
	<mesh_term>Epilepsy</mesh_term>
	<criteria>Male/female 16 65 year . Wellcharacterized focal epilepsy epileptic syndrome accord International League Against Epilepsy ( ILAE ) classification . History partial onset seizure . Subjects least 4 partial onset seizures 4week Baseline Period least 2 partial onset seizures 3 month prior Visit 1 . Subjects take 1 2 concomitant Antiepileptic drug ( AED ( ) ) stable dose . Seizure type IA nonmotor seizure type . Seizures occur cluster . Status epilepticus last 2 year Visit 1 . History cerebrovascular accident ( CVA ) . Presence sign suggest rapidly progress brain disorder brain tumor .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Epilepsy : partial onset seizure</keyword>
	<keyword>brivaracetam</keyword>
</DOC>